Sandrine Cammas-Marion. Degradable and biocompatible nanoparticles decorated with cyclic RGD peptide for efficient drug delivery to hepatoma cells in vitro.
2 HepaRG hepatoma cells than biotinylated fluorescent NPs. Furthermore, the targeting of HepaRG 26 hepatoma cells with NPs bearing cyclic RGD was very efficient and much weaker for HeLa and HT29 27 cell lines confirming that cyclic RGD is a suitable targeting agent for liver cells. Our results also 28 provide a new mean for rapid screening of short hepatotropic peptides in order to design NPs showing 29 specific liver targeting properties. bioavaibility within solid tumors, arising from a decrease in its non-specific recognition by the 38 reticuloendothelial system (RES) and an improvement of its in vivo specific biodistribution, as well as 39 a minimized toxicity against healthy tissues and organs [Yan et al., 2012; Elsaesser et al., 2012; 40 Lamprecht, 2008] . Knowing that cancer, characterized by an abnormal and anarchical cell proliferation 41 within normal tissue, is a very complex disease and a major cause of mortality [Misra et al., 2010] , the 42 development of efficient nanomedicine is thus a major challenge for public health [Reddy et al., 2011] . 43
In this context, several anti-cancer drug loaded NPs such as Doxyl® and Abraxane® have been 44 approved by the Food and Drug Administration (FDA) for clinical uses [Yan et al., 2012; Wang et al., 45 The materials constituting the NPs have to respect very strict specifications: they must be (i) 48 biocompatible and non-toxic, (ii) (bio)degradable into non-toxic low molecular weight molecules or, at 49 least, bioassimilable after releasing the encapsulated drug, (iii) undetectable by the RES meaning 50 having stealth properties, (iv) adapted for carrying large amounts of drug that should be released in a 51 3 controlled manner at its site of action (targeting). Within this context, we have recently developed a 52 family of degradable non-toxic polymers derived from poly(malic acid), PMLA, which are able to 53 form well-defined NPs [Huang et al., 2012] . We have selected PMLA as macromolecular backbone 54 because this polymer, originally synthesized for application in the biomedical field, has been 55 successfully used as a platform in the synthesis of nanovectors [Huang et al., 2012 [Vert et al., 1979] and its derivatives are accessible from naturally occurring 60 PMLA [Ljubimova et al., 2008] or by anionic ring-opening polymerization (ROP) of β-substituted β-61 lactones [Cammas et al., 1996; Cammas et al., 1993] . PMLA derivatives used for the formulation of 62 NPs were obtained by ROP of benzyl malolactonate (MLABe) in presence of either 63 tetraethylammonium benzoate, α-methoxy ω-carboxy poly(ethylene glycol) -PEG 42 -CO 2 H-or α-biotin 64 ω-carboxy poly(ethylene glycol) -Biot-PEG 62 -CO 2 H-as initiator [Huang et al., 2012] . Starting from 65 these three PMLA derivatives, we were able to obtain well-defined non-toxic NPs in which the 66 doxorubicin (Dox), and a fluorescent probe, the DiD oil, have been successfully encapsulated for in 67 vitro assays [Huang et al., 2012] . It is worth noting that PEG has been selected as hydrophilic block 68 because it is a well-known polymer conferring stealth properties at nanoparticles on which it is grafted 69 [Romberg et al., 2008] . On the other hand, biotin has been chosen firstly because it is a targeting agent 70 of certain cancer cells [Le Droumaguet et al., 2012; Patil et al., 2099; Kim et al., 2007] and secondly 71 because it is able to interact strongly with streptavidin [Yang et al., 2009] which is an important 72 property for our study as it will be explained afterwards in this paper. 73
Hepatocellular carcinoma (HCC) is the main primary malignant tumor of the liver representing 80 to 74 90% of liver tumors. It is the fifth most common tumor worldwide (5.4% of new cancer cases per year) 75 and the third in term of mortality (8.2% of all cancer death) [Parkin et al., 2005] . Early detection and 76 classification of HCC are crucial for the choice and effectiveness of therapeutic strategy. For small size 77 4 HCC, surgical treatment (resection and liver transplantation) is the most effective treatment [Hasegawa 78 et al., 2009; Mazzeferro et al., 2008; Ishikawa et al., 1992] . Palliative treatments such as 79 chemoembolization [Bernades-Genisson et al., 2003 ] and, more recently, chemotherapy using an 80 inhibitor of tyrosine kinase, Sorafenib (Nexavar®) are proposed to patients with advanced HCC. 81
Despites these advances, the therapeutic options for the treatment of HCC remains limited partly due 82 to the chemoresistance of liver tumors to conventional anti-tumor agents. Therefore, the use of 83 nanocarriers containing anti-tumor drugs has been envisaged for the treatment of HCC in order to 84 increase the intra-hepatic drug concentration while limiting the exposure of healthy tissues and side 85 effects [Reddy et al., 2011] . Several formulations are currently undergoing clinical trials in phase II 86 and III such as NPs of poly(alkyl cyanoacrylate) loaded with doxorubicin (Trandrug®) for HCC 87 treatment [Barraud et al., 2005] . In a first step, the passive accumulation of nanocarriers in the RES 88 cells (endothelial and Kupffer cells) [Lanaerts et al., 1984] was utilized for liver targeting with a real 89 relevance for diseases involving liver Kupffer cells such as parasitic diseases [Alving et al., 1978] . 90
Conversely, liver targeting based on the nanocarrier's uptake by Kupffer cells has the major drawback 91 of allowing only a low hepatic accumulation of nanocarriers since Kupffer cells represent only a few 92 percent of liver cell volume against 90% for hepatocytes. In addition, the accumulation of nanocarriers 93 in Kupffer cells does not target the cells responsible for HCC thus limiting the use of this approach in 94 this case. Therefore, to overcome this drawback, active hepatocyte targeting has been studied. Most of 95 the proposed strategies are based on the binding of NPs to the asialoglycoprotein receptors [Wu et al., 96 2002 ]. These NPs are usually liposomes incorporating glycosylated proteins or galactose/lactose linked 97 to lipophilic anchors [Wu et al., 2002] . To date, very few nanovectors, especially polymer-based NPs, 98 carrying peptides with high tropism for the liver have been developed [Reddy et al., 2011] . 99
In this paper, we report, first, the monitoring of Dox release from NPs prepared from PEG 42 -b-100 PMLABe or Biot-PEG 62 -b-PMLABe in water and in culture medium at 37°C. Second, we have grafted 101 fluorescein amine (FA) molecule at the free end of the PMLABe block of PEG 42 -b-PMLABe or Biot-102 PEG 62 -b-PMLABe block copolymers in order to obtain fluorescent NPs for in vitro cell uptake assays. 103 5 Starting from the corresponding fluorescent NPs, we have studied the influence of the nature of 104 molecules localized at NPs' surfaces [PEG 42 , Biot-PEG 62 or Arginine-Glycine-Aspartic acid (RGD) 105 peptide-Biot-Streptavidin-Biot-PEG 62 ] on their internalization into cells in vitro and demonstrated that 106 the uptake by HepaRG hepatoma cells is considerably enhanced by the grafting of the RGD peptide 107 onto NPs. These results also show that these biotinylated NPs can be useful tools for rapid in vitro 108 screen and selection of highly hepatotropic peptides with the ultimate goal to design nanomedicine 109 targeting hepatocytes from HCC in vivo. The PEG 42 -b-PMLABe block copolymer (500 mg) was dissolved into 1 mL of anhydrous CH 2 Cl 2 140 under nitrogen atmosphere. To this solution were added 5 mg (1eq.) of N,N'-diclohexylcarbodiimide 141 (DCC) dissolved in 1 mL of anhydrous CH 2 Cl 2 followed by 7.5 mg (1eq.) of N-hydroxysuccinimide 142 (NSH) dissolved in 1 mL of anhydrous CH 2 Cl 2 . The mixture was stirred under nitrogen atmosphere for 143 24 hours at room temperature (RT). The resulting PEG 42 -b-PMLABe-NHS was precipitated in cold 144 heptane. After the elimination of the supernatant, the precipitate was dissolved in CH 2 Cl 2 and the 145 solution was filtrated on celite. The CH 2 Cl 2 was eliminated under vacuum and the activated block 146 copolymer polymer (480 mg) was obtained with 96% yield. The activated block copolymer (480 mg) 147 was then dissolved in 1 mL of anhydrous CH 2 Cl 2 . To this solution was added 12 mg of FA (1eq.) 148 solubilised into a mixture of 1 mL of anhydrous CH 2 Cl 2 and 1 mL of acetone HPLC grade under 149 nitrogen atmosphere. After stirring at RT for 24 hours, the solution containing the PEG 42 -b-PMLABe-150 FA block copolymer was precipitated into cold heptane. After removing the supernatant, the 151 precipitate was dissolved into DMSO. This DMSO solution was poured into a dialysis bag (MWCO 152 3,500 Da) and the dialysis was conducted during 8 hours against DMSO. The solution contained into 153 the dialysis bag was lyophilized and the PEG 42 -b-PMLABe-FA block copolymer was recovered with 154 60% yield. The polymer was characterized by 1 H NMR in deuterated DMSO. 155 7 1 H NMR (d6-DMSO, δ ppm): 2.92 (s, 2nH, CO 2 CH 2 C 6 H 5 ), 3.32 (m, 4mH (m=42), (CH 2 CH 2 O) 42 ), 5.10 156 (m, 2nH, CHCH 2 CO 2 ), 5.42 (m, 1nH, CHCH 2 CO 2 ), 6.50-7.00 (m, 9H, FA); 7.31 (m, 5nH, 157 CO 2 CH 2 C 6 H 5 ). 158 M NMR = 11,000 g/mol for the PMLABe block 159 160 2.4.2 Grafting of FA on the Biot-PEG 62 -b-PMLABe block copolymer (Scheme 1) 161
The grafting of FA on the Biot-PEG 62 -b-PMLABe block copolymer was realized as described above. 162
The Biot-PEG 62 -b-PMLABe-FA block copolymer was obtained with 58% yield and characterized by 163 The protocol for Dox encapsulation and for the monitoring of its release was the same whatever the 173 nature of the block copolymer constituted the NPs. The encapsulation of Dox into the NPs was realised 174 as described previously [Huang et al., 2012] . Briefly, the Dox hydrochloride (Dox,HCl, Sigma) was 175 encapsulated into the two kinds of NPs during the nanoprecipitation procedure. The selected polymer 176 (5 mg) was dissolved in acetone (1 mL). Two hundred µL of a Dox solution [1.5 mg of Dox,HCl 177 solubilised in 0.6 mL of a mixture of chloroform (6 mL) and NEt 3 (23 µL)] were added to the polymer 178 solution. This mixture was then nanoprecipitated into 2 mL of water under vigorous stirring. After 179 organic solvent evaporation, the unloaded Dox was removed by ultracentrifugation at 15,000 g at 15°C 180 for 7 min using filter with an exclusion limit 10,000 Da. The filters were returned and centrifuged for 1 181 8 min at 1,000 g at 15°C. The volume of the recovered solutions was completed to 2 mL with distilled 182 water in order to obtain a final concentration in NPs of 2.5 g/L. The concentration of loaded Dox was 183 evaluated by UV at 485 nm, as described elsewhere [ The characteristics of the Dox-loaded NPs (diameter, polydispersity index and zeta potential) were 191 measured using the Delsa™ Nano Beckman Coulter apparatus (Table 1) . 192
The Dox release from both kinds of NPs were monitoring by dialysis in water and in culture medium completed to 2 mL with fresh water. The final concentration in block copolymers under NPs' form was 208 2.5 g/L. The solutions containing the fluorescent NPs were characterized by dynamic light scattering 209 using a Delsa™ Nano Beckman Coulter apparatus at 25°C (Table 2) have no influence on NP's characteristics, we analyzed the NPs formed in the conditions described 223 above by DLS (Table 3) 2.10 6 cells were seeded in a 75 cm 3 flask. The medium was renewed every 48 hours. The sub-culturing 231 was realized by trypsinization every 2 weeks in order to maintain the progenitor phenotype. For an 232 10 optimal differentiation, the cells were maintained at confluence after the two weeks and the medium 233 was supplemented with 2% of dimethylsulfoxide (DMSO) [Laurent et al., 2013] . 234
For the cell uptake assays, the 24 wells culture plates were seeded with the selected cell line (HepaRG, 235 HT29 or HeLa) with 10 5 cells per well. Then the NPs' preparations (4µM of block copolymer under 236
NPs' form ± 4 µM streptavidin and 8 µM Biot-RGD) or a negative control (buffer without NPs or non 237 fluorescent NPs) were added to the wells. For the competitive experiments, the cells were pre-treated 238 with an excess of free RGD peptide (32 µM). 239
The cells were incubated from 1 to 24 hours. After incubation, the culture medium was removed; the 240 cell monolayers were washed with PBS before the observation by fluorescence microscopy (Zeiss 241 inverted microscope, analysis software AxioVision). Then the cells were detached with trypsin and 242 forming NPs, it will be necessary to realize further experiments such as X-ray measurements. 284
Nevertheless, these results are quite encouraging because we are able to encapsulate substantial 285 amount of this drug and the release profile is in agreement with the Dox amphiphilic nature. 286 287
Grafting of fluorescein amine and cellular uptake assays 288
Besides the use of biotin as a well-known targeting agent of cancer cells [Yang et al., 2009 ], we aimed 289 at developing a versatile procedure to screen for more specific targeting agents, especially short 290 peptides, towards transformed hepatocytes from hepatocellular carcinoma (HCC). 291
Our goal is to select peptides exhibiting a remarkably high tropism for the hepatocytes as targeting 292 agents and to graft them at the surface of PMLA derivatives-based NPs in order to achieve an 293 optimized uptake of NPs by the hepatocytes. In a first step, we wish to screen, rapidly and in a simple 294 manner without engaging more organic chemistry, a large number of peptides which potentially show 295 a strong hepatotropism to select the most efficient ones. For that purpose, we used the non-covalent 296 binding of selected peptides via the strong biotin-streptavidin affinity as shown by Figure 3 b-PMLABe-FA NPs was very limited compared to negative control cells exposed to the non-373 fluorescent NPs demonstrating that the biotin did not trigger a strong captation. Addition of the RGD 374 peptide led to strong increase in the fluorescence level within HepaRG cells reaching a mean of ~1500 375 U.A and with over 90% of positive cells (Figure 4) . These data demonstrate that the addition of the 376 RGD peptide onto NPs has considerably enhanced the cell uptake of the NPs. 377
We then followed the time course of uptake by HepaRG cells of NPs formed by Biot-PEG 62 -b-378
PMLABe-FA or Biot-RGD-Strept-Biot-PEG 62 -b-PMLABe-FA by flow cytometry analysis at 2, 6, 14 379 and 24 hours of incubation. As shown by figure 5, the results of mean of fluorescence intensity 380 indicated a very rapid uptake within the first 6 hours which continued slower until 24 hours for RGD-381
Biot-Strept-Biot-PEG 62 -b-PMLABe-FA based NPs (Figure 5, red HepaRG cells by comparing the efficiency of the uptake in absence or presence of an excess of free 389 RGD peptide at a concentration of 34 µM ( Figure 6 ). The results of fluorescence intensity measured by 390 flow cytometry indicated that the pre-incubation of HepaRG cells with free RGD peptide before the 391 addition of RGD modified fluorescent NPs strongly inhibited the cell uptake. Therefore, we can 392 conclude that the presence of the RGD peptide at the NP's surfaces is responsible for the increase in 393
HepaRG cell uptake of NPs. PMLABe-FA NPs for 24 hours demonstrating that these biotinylated NPs are poorly uptaken by cells 405 from different tissue origin. Importantly, the three cell types exhibited very different uptake of the 406 RGD-Biot-Strept-Biot-PEG 62 -b-PMLABe-FA formed NPs. The number of positive HT29 cells is very 407 low (< 5%) while about 90% of HeLa cells captured the RGD modified fluorescent NPs (Figure 7) . 408
However, the degree of uptake (fluorescence intensity) in HeLa cells is much lower than the one 409 observed for HepaRG cells (Figure 7) . This result suggested that the number of membrane receptors 410 binding RGD peptide (integrin family members) on HeLa cells is sufficient to trigger the uptake of 411
NPs by most of the cells. However, the density of these receptors onto HeLa cells might be lower than 412 onto HepaRG cells leading to a higher degree of NPs captation by the hepatoma cells than the HeLa 413 cells. 414 415
Conclusions 416
In this study, we have demonstrated a rapid release of the Dox from PEG 42 -b-PMLABe and Biot-417 PEG 62 -b-PMLABe NPs over the first 6 hours. However, the NPs, which are stable in water and culture 418 medium for several days, entrapped a fraction of the drug that is slowly released over several days. 419
Then, we characterized the cell uptake of PEG 42 -b-PMLABe and Biot-PEG 62 -b-PMLABe NPs using 420 fluorescein amine modified polymers. We demonstrated that biotinylated NPs modified with the cyclic 421 RGD peptide significantly increase the uptake by HepaRG cells in comparison to NPs formed by Biot-422 PEG 62 -b-PMLABe-FA without peptide. We have also proved that this capture was dependent on the 423 presence of the RGD peptide because the addition of an excess of free RGD peptide strongly inhibited 424 the uptake. In addition, our results indicate that the RGD peptide presents a real tropism for liver cells 425 since its uptake by HeLa and HT29 cells was much lower than the uptake by HepaRG cells. These 426 results should be complemented by a larger study including other liver and non-hepatic cell lines as 427 well as primary cells such as endothelial cells and normal hepatocytes. Our study also provides a proof 428 of concept for the use of the versatile molecular scaffold presented in Figure 3 in order to screen for 429 other short peptides targeting hepatocytes and HCC. Since we have shown that it was possible to use 430 the streptavidin to graft a biotinylated peptide onto the biotin present at the surface of Biot-PEG 62 -b-431
PMLABe based NPs, we are evaluating a number of peptides without having to engage additional 432 chemistry. The most efficient peptides will be then grafted at the end of the hydrophilic PEG block to 433 avoid the use of immunogenic streptavidin for further in vivo biodistribution assays. 
